Praxis Precision Medicines ‘A Diversified Player In Epilepsy Market,’ Analyst Sees Over 100% Stock Upside

Chardan initiates Praxis with a Buy rating, highlighting its epilepsy pipeline, strong cash position, and billion-dollar potential of vormatrigine. Latest Ratings for PRAX Date Firm Action From To Dec 2021 HC Wainwright & Co. Initiates Coverage On Buy Aug 2021 B of A Securities Initiates Coverage On Buy Apr 2021 William Blair Initiates Coverage On…

Read More